TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models.

Jie Yu, Jonathan Zalevsky, Jessica Huck Sappal et al.|Journal of Clinical Oncology|2018

Cited by 0